In vitro effect of novel β-lactam compounds on xanthine oxidase enzyme activity

References

• Andersen JM, Dietschy J. 1976. Cholesterogenesis: derepression in extrahepatic tissues with 4-aminopyrazolo (3,4-d) pyrimidine. M. Science 193:903–905.
   PubMed Web of Science ®Google Scholar
• Aydemir T, Kavrayan D. 2009. Purification and characterization of glutathione-S-transferase from chicken erythrocyte. Artif Cells Blood Substit Immobil Biotechnol 37:92100.
   PubMed Web of Science ®Google Scholar
• Banner DW, Hadvary PJ. 1991. Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of 4 active site-directed inhibitors. J Biol Chem 266:20085.
   PubMed Web of Science ®Google Scholar
• Bashir S, Shah SM, Babar IJ. 2000. Allopurinol induced Stevens- Johnson syndrome: A case report. Pak Med Assoc 50:207.
   PubMedGoogle Scholar
• Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, MacDonald P, and Joseph-Ridge N. 2004. (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleo. Nucleotides Nucleic Acids 8–9:1111–116.
   Google Scholar
• Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, and Joseph-Ridge N. 2005. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353:2450–2461.
   Web of Science ®Google Scholar
• Berry CE and Hare JM. 2004. Xanthine oxidoreductase and cardiovascular disease: Molecular mechanisms and pathophysiological implications. J. Physiol. (Lond) 555:589–606.
   Google Scholar
• Beyaztas S, and Arslan O. 2011. Effects of some antibiotics on xanthine oxidase enzyme activities in vitro. Hacettepe J. Biol. & Chem. 39(2):205.
   Google Scholar
• Borges F, Fernandes E and Roleira F. 2002. Progress towards the discovery of xanthine oxidase inhibitors. Curr. Med. Chem. 9:195–217.
   PubMed Web of Science ®Google Scholar
• Bradford MM. 1976. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248.
   PubMed Web of Science ®Google Scholar
• Clemente A, Domingos A, Grancho AP, Iley J, Moreira R, Neres J, Palma N, Santana AB, Valente E. 2001. Design, synthesis and stability of n-acyloxymethyl- and n-aminocarbonyloxymethyl-2-azetidinones as human leukocyte elastase inhibitors. Bioorg Med Chem Lett 11:1065.
   PubMed Web of Science ®Google Scholar
• Elriati A, Loose J, Mayrhofer R, Bergmann H J, and Otto HH. 2008. β-lactam derivatives as enzyme inhibitors: Halogenated β-lactams and related compounds. Monatsh Chem 139:835.
   Web of Science ®Google Scholar
• Fernandes E, Carvalho F, Silva AM, Santos CM, Pinto DC, Cavaleiro JA, Bastos Mde LJ. 2002. 2-styrylchromones as novel inhibitors of xanthine oxidase: A structure-activity study. J. Enzyme Inhib. Med. Chem. 17:45–48.
   Web of Science ®Google Scholar
• Fukunari A, Okamoto K, Nishino T, Eger BT, Pai EF, Kamezawa M, Yamada I, and Kato N. 2004. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion. J. Pharmacol. Exp. Ther. 311:519–528.
   Google Scholar
• Gencer N, Arslan O. 2011. in vitro effects of some pesticides on PON1Q192 and PON1R192 isoenzymes from human serum. Fresen. Envir. Bull. 20:590–596.
   Google Scholar
• Gencer N, Arslan O. 2009. Purification human PON1(Q192) and PON1(R192) isoenzymes by hydrophobic interaction chromatography and investigation of the inhibition by metals J. Chrom. B-Anal. Tech. Biomed. Life Sci. 877:134–140.
   Web of Science ®Google Scholar
• Georg GI, Ravikumar VT. 1992. The Organic Chemistry of β-lactams. Weinheim: VCH Publishers.
   Google Scholar
• Hammer B, Link A, Wagner A, Bohm M. 2001. Fatal allopurinol- induced hypersensitivity syndrome in asymptomatic hyperuricaemia. Dtsch Med Wochenschr 126:1331.
   PubMed Web of Science ®Google Scholar
• Harris MD, Siegel LB, Alloway JA. 1999. Gout and hyperuricemia. Am. Fam. Physician. 59:925.
   Google Scholar
• Harrison R. 2002. Structure and function of xanthine oxidoreductase: Where are we now? Free Radic Biol. Med. 33:774–797.
   Web of Science ®Google Scholar
• Harrison R. 2004. Physiological roles of xanthine oxidoreductase. Drug Metab. Rev. 36:363–375.
   Google Scholar
• Hashimoto T, Fukunari A, Yamada I, Yanaka N, Chen D, and Kato N. 2005. Y-700, a novel inhibitor of xanthine oxidase, suppresses the development of colon aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine-treated mice. Biosci. Biotechnol. Biochem. 69:209–211.
   Web of Science ®Google Scholar
• Henderson JF, Junga IG. 1961. The metabolism of 4-aminopyrazolo(3,4-d)pyrimidine in normal and neoplastic tissues. Cancer Res. 21:118–129.
   PubMed Web of Science ®Google Scholar
• Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, Ohno I, and Hosoya T. 2004. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleo. Nucleotides Nucleic Acids 23:1117.
   PubMed Web of Science ®Google Scholar
• Hsieh JF, Wu SH, Yang YL, Choong KF and Chen ST. 2007. The screening and characterization of 6-aminopurine-based xanthine oxidase inhibitors. Bioorg Med Chem 15:3450.
   PubMed Web of Science ®Google Scholar
• Ishibuchi S, Morimoto H, Oe T, Ikebe T, Inoue H, Fukunari A, Kamezawa M, Yamada I, Naka Y. 2001. Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. Bioorg Med Chem Lett 11:879.
   PubMed Web of Science ®Google Scholar
• Isik S, Kockar F, Aydin M, Arslan O, Guler OO, Innocenti A, Scozzafava A, Supuran CT. 2009. Carbonic anhydrase inhibitors: Inhibition of the beta-class enzyme from the yeast saccharomyces cerevisiae with sulfonamides and sulfamates. Bioorg Med Chem 17(3):1158.
   PubMed Web of Science ®Google Scholar
• Kiranoglu S, Sinan S, Gencer N, Kockar F, Arslan O. 2007. In vivo effects of oral contraceptives on paraoxonase, catalase and carbonic anhydrase enzyme activities on mouse. Biolog. Pharm. Bull. 30:1048–1051.
   Google Scholar
• Komoriya K, Hoshide S, Takeda K, Kobayashi H, Kubo J, Tsuchimoto M, Nakachi T, Yamanaka H, and Kamatani N. 2004. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleo. Nucleotides Nucleic Acids 23:1119–1122.
   PubMed Web of Science ®Google Scholar
• Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680.
   PubMed Web of Science ®Google Scholar
• Manfredi JP and Holmes EW. 1985. Purine salvage pathways in myocardium. Annu. Rev. Physiol. 47:691–705.
   Web of Science ®Google Scholar
• Massey V, Brumby PE, Komai H. 1969. Studies of milk xanthine oxidase: Some spectral and kinetic properties. J Biol Chem 244:1682.
   PubMed Web of Science ®Google Scholar
• Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, and Mulford DJ. 2005. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am. J. Ther. 12:22–34.
   Google Scholar
• McManaman JL, Shellman V, Wright RM, Repine JE. 1996. Purification of rat liver xanthine oxidase and xanthine dehydrogenase by affinity chromatography on benzamidine-sepharose. Archives of Biochemistry and Biophysics, 332(1):135–141.
   PubMed Web of Science ®Google Scholar
• Naito S, Nishimura M, and Tamao Y. 2000. Evaluation of the pharmacological actions and pharmacokinetics of BOF-4272, a xanthine oxidase inhibitor, in mouse liver. J. Pharm. Pharmacol. 52:173–179.
   Web of Science ®Google Scholar
• Nguyen MT, Awale S, Tezuka Y, Ueda JY, Tran Q, Kadota S. 2006. Xanthine oxidase inhibitors from the flowers of Chrysanthemum sinense. Planta Med. 72:46–51.
   PubMed Web of Science ®Google Scholar
• Ojima I. 1995. Recent advances in the beta-lactam synthon method. Acc. Chem. Res. 28:383.
   Google Scholar
• Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF and Nishino T. 2003. An extremely potent inhibitor of xanthine oxidoreductase crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biolog Chem 278:1848–1855.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Matsumoto K, Hille R, Eger BT, Pai EF, and Nishino T. 2004. The crystal structure of xanthine oxidoreductase during catalysis: Implications for reaction mechanism and enzyme inhibition. Proc. Natl. Acad. Sci. USA 101:7931–7936.
   PubMed Web of Science ®Google Scholar
• Özer N, Müftüoglu M, Ataman D, Ercan A, Ögüs IH. 1999. Simple, high-yield purification of xanthine oxidase from bovine milk. J Biochem Biophys Methods 39:153.
   PubMedGoogle Scholar
• Pacher P, Nivorozhkin A, and Szabo C. 2006a. Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58:87–114.
   PubMed Web of Science ®Google Scholar
• Pacher P, Nivorozhkin A, and Szabo C. 2006b. Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacol. Rev. 58:87–114.
   Google Scholar
• Rang HP, Dale MM, Ritter JM. 1999. In: Ritter, J. Ed.; Pharmacology. New York: Pergamon Press. pp. 239–246.
   Google Scholar
• Sandstrom E. 1989. Antiviral therapy in human immunodeficiency virus-infection. Drugs 38:417.
   PubMed Web of Science ®Google Scholar
• Sathisha KR, Khanum SA, Chandra JNNS, Ayisha F, Balaji S, Marathe GK, Gopal S, Rangappa KS. 2011. Synthesis and xanthine oxidase inhibitory activity of 7-methyl-2-(phenoxymethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one derivatives. Bioorg Med Chem 19:211.
   PubMed Web of Science ®Google Scholar
• Sheu SY, Lin YC, Chiang HC. 1997. Inhibition of xanthine oxidase by synthetic cytokinin analogues. Anticancer Res 17:1043–1049.
   PubMed Web of Science ®Google Scholar
• Sinan S, Gencer N, Turan Y, Arslan O. 2007. in vitro inhibition of the carbonic anhydrase from saanen goat (capra hircus) with pesticides. Pest. Biochem. Phys. 88:307–311.
   Google Scholar
• Sinan S, Kockar F, Gencer N, Yildirim H, Arslan O. 2006. Amphenicol and macrolide derived antibiotics inhibit paraoxonase enzyme activity in human serum and human hepatoma cells (HepG2) in vitro. Biochem.Moscow 71(1):46–50.
   PubMed Web of Science ®Google Scholar
• Stevens CR, Millar TM, Clinch JG, Kanczler JM, Bodamyali T, Blake DR. 2000. Antibacterial properties of xanthine oxidase in human milk. The Lancet 356:829.
   PubMed Web of Science ®Google Scholar
• Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, and Becker MA. 2005. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 76:1835–1847.
   PubMed Web of Science ®Google Scholar
• Tamta H, Kalra S, Mukhopadhyay AK. 2006. Biochemical characterization of some pyrazolopyrimidine-based inhibitors of xanthine oxidase. Biochemistry Mosc. 71:49–54.
   Web of Science ®Google Scholar
• Tamta H, Thilagavathi R, Chakraborti AK, Mukhopadhyay AKJ. 2005. 6-(N-benzoylamino)purine as a novel and potent inhibitor of xanthine oxidase: Inhibition mechanism and molecular modeling studies . Enz Inhib Med Chem 20:317.
   PubMed Web of Science ®Google Scholar
• Tamta H, Kalra S, Mukhopadhyay AK. 2006. Biochemical characterization of some pyrazolopyrimidine-based inhibitors of xanthine Xoxidase. Biochemistry Mosc 71:S49–545.
   Web of Science ®Google Scholar
• Yamada I, Fukunari A, Osajima T, Kamezawa M, Mori H, and Iwane J. 2004. Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man. Nucleo. Nucleotides Nucleic Acids 23:1123–1125.
   PubMed Web of Science ®Google Scholar
• Yamamoto T. 2003. Development antihyperuricemic candidates. Nippon Rinsho 61(Suppl 1):209–212.
   PubMedGoogle Scholar